GlassScriptPhysician profile
Jefferson K Davis
NPI 1669523502
$53,094.97
in general payments reported to CMS, 2019-2025
19 companies · $27.16 in 2025
The $27.16 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,782 · 2021: $8,795 · 2022: $21K · 2023: $8,293 · 2024: $301 · 2025: $27.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,070 · Food and Beverage: $1,270 · Consulting Fee: $200 · Travel and Lodging: $80.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,070.00 |
| Food and Beverage | $1,270.15 |
| Consulting Fee | $200.00 |
| Travel and Lodging | $80.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23,708.02 | 2021-2024 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $18,400.80 | 2019-2023 | Uzedy, Austedo, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $6,244.08 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $1,030.66 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $841.15 | 2020-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $709.08 | 2019-2025 | Entyvio, Trintellix |
| Merck Sharp & Dohme LLC | $439.16 | 2019-2023 | Belsomra |
| Lundbeck LLC | $322.64 | 2019-2023 | Rexulti |
| Allergan, INC. | $310.83 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $263.61 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $200.00 | 2024 | Spravato |
| Axsome Therapeutics, INC. | $127.92 | 2022-2023 | Auvelity |
| Eisai INC. | $105.86 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $95.07 | 2019-2020 | |
| Alkermes, INC. | $73.88 | 2022-2023 | Aristada, Lybalvi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $65.40 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $62.45 | 2022-2023 | Qelbree |
| Neurocrine Biosciences, INC. | $55.24 | 2019-2022 | |
| Corium, LLC | $39.12 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jefferson Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.